MTOR and acute myeloid leukemia: Active surveillance is the most common sAML disease management option not involving an invasive kidney intervention, although mammalian target of rapamycin inhibitors (mTORi) may be used off-label in some patients with sAML, based on their mechanism of action in TSC-related AML [16].